Abstract | BACKGROUND: METHODS: In this paper we report preliminary results from an ongoing clinical observational "real life" surveillance-based study focused on effects of this therapy on non-motor symptoms and health-related quality of life in a group of patients on apomorphine. RESULTS:
Apomorphine infusion led to highly significant improvements in UPDRS 3 (p = 0.0003), UPDRS 4 (p = 0.0003), PDQ-8 ( Parkinson's disease questionnaire, p = 0.001) and NMSS total (non motor symptoms scale, p = 0.0003). Furthermore, apomorphine was tolerated in patients with visual hallucinations, illusions and paranoid ideations while significant improvement in specific non-motor symptoms such as hyperhidrosis, nocturia, urgency of micturition, and fatigue was recorded. Levodopa equivalent dose decreased significantly (1077.81 ± 446.26 to 458.75 ± 282.29, p < 0.0001) and a large effect size of intervention was noted. In an untreated group no such improvement was noted. The number needed to treat (NNT) for improvement >1 SEM in the Apo group was calculated and was lower than 2 for >1 SEM improvement of UPDRS 3, NMSS, and PDQ-8 total scores. CONCLUSIONS:
|
Authors | Pablo Martinez-Martin, Prashanth Reddy, Angelo Antonini, Tove Henriksen, Regina Katzenschlager, Per Odin, Antonia Todorova, Yogini Naidu, Susanne Tluk, Chandni Chandiramani, Anne Martin, Kallol Ray Chaudhuri |
Journal | Journal of Parkinson's disease
(J Parkinsons Dis)
Vol. 1
Issue 2
Pg. 197-203
( 2011)
ISSN: 1877-718X [Electronic] Netherlands |
PMID | 23934921
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Dopamine Agonists
- Apomorphine
|
Topics |
- Aged
- Apomorphine
(administration & dosage)
- Chi-Square Distribution
- Dopamine Agonists
(administration & dosage)
- Drug Administration Routes
- Female
- Humans
- Infusions, Subcutaneous
- Male
- Middle Aged
- Observation
- Parkinson Disease
(complications, drug therapy)
- Pilot Projects
- Quality of Life
- Severity of Illness Index
|